Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells

Biochemical Pharmacology

Volumn 80, Issue 6, 2010, Pages 846-857

  Ramer, Robert ^a   Hinz, Burkhard ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Antiglaucomatous drugs; Cannabinoids; Cyclooxygenase 2; Migration; Prostaglandins; Tissue inhibitor of matrix metalloproteinases 1; Trabecular meshwork cells

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; METHANANDAMIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; RECOMBINANT ENZYME; SMALL INTERFERING RNA; TETRAHYDROCANNABINOLIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TRABECULAR MESHWORK; UPREGULATION;

ARACHIDONIC ACIDS; CELL LINE, TRANSFORMED; CELL MIGRATION INHIBITION; CELL SURVIVAL; CYCLOOXYGENASE 2; HUMANS; TETRAHYDROCANNABINOL; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRABECULAR MESHWORK;

EID: 77954760593     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.05.010     Document Type: Article

References (59)

1. Jarvinen T., Pate D.W., Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002, 95:203-220.
2. Hepler R.S., Frank I.R. Marihuana smoking and intraocular pressure. J Am Med Assoc 1971, 217:1392.
3. Flom M.C., Adams A.J., Jones R.T. Marijuana smoking and reduced pressure in human eyes. Invest Ophthalmol 1975, 14:52-55.
4. 9-Tetrahydrocannabinol, euphoria and intraocular pressure in man. Ann Ophthalmol 1975, 7:921-923.
5. Colasanti B.K. Ocular hypothensive effect of marihuana canabinoids: correlate of central action or separate phenomenon?. J Ocular Pharmacol 1986, 2:295-304.
6. Pate D.W., Jarvinen K., Urtti A., Jarho P., Jarvinen T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res 1995, 14:791-797.
7. Juntunen J., Huuskonen J., Laine K., Niemi R., Taipale H., Nevalainen T., et al. Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide. Eur J Pharm Sci 2003, 19:37-43.
8. Pate D.W., Jarvinen K., Urtti A., Jarho P., Fich M., Maahadevan V., et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci 1996, 58:1849-1860.
9. 9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001, 33:217-220.
10. Weinreb R.N., Toris C.B., Gabelt B.T., Lindsey J.D., Kaufman P.L. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002, 47(Suppl. 1):S53-S64.
11. Rösch S., Ramer R., Brune K., Hinz B. R(+)-Methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther 2006, 316:1219-1228.
12. Tamm E.R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 2009, 88:648-655.
13. Zhou L., Li Y., Yue B.Y. Alteration of cytoskeletal structure, integrin distribution, and migratory activity by phagocytic challenge in cells from an ocular tissue-the trabecular meshwork. In Vitro Cell Dev Biol Anim 1999, 35:144-149.
14. Grierson I., Wang D., McMenamin P.G., Lee W.R. The effects of age and antiglaucoma drugs on the meshwork cell population. Res Clin Forums 1982, 4:69-92.
15. Alvarado J., Murphy C., Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and non glaucomatous normals. Ophthalmology 1984, 91:564-579.
16. Grierson I., Howes R.C. Age-related depletion of the cell population in the human trabecular meshwork. Eye 1987, 1:204-210.
17. Grierson I., Hogg P. The proliferative and migratory activities of trabecular meshwork cells. Prog Retin Eye Res 1995, 15:33-67.
18. Grierson I., Calthorpe C.M. Characteristics of meshwork cells and age changes in the outflow system of the eye: their relevance to primary open angle glaucoma. Glaucoma 1989, 12-31. Persimmon Press, Oxford. K.B. Mills (Ed.).
19. Hogg P., Calthorpe M., Batterbury M., Grierson I. Aqueous humor stimulates the migration of human trabecular meshwork cells in vitro. Invest Ophthalmol Vis Sci 2000, 41:1091-1098.
20. Njie Y.F., Qiao Z., Xiao Z., Wang W., Song Z.H. N-Arachidonylethanolamide-induced increase in aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2008, 49:4528-4534.
21. Njie Y.F., He F., Qiao Z., Song Z.H. Aqueous humor outflow effects of 2-arachidonylglycerol. Exp Eye Res 2008, 87:106-114.
22. 1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2006, 47:1999-2005.
23. McIntosh B.T., Hudson B., Yegorova S., Jollimore C.A., Kelly M.E. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 2007, 152:1111-1120.
24. 2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2005, 46:1988-1992.
25. 1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties. Mol Vis 2006, 12:290-297.
26. 2 cannabinoid receptors in trabecular meshwork cells. Mol Vis 2007, 13:1348-1356.
27. Ramer R., Weinzierl U., Schwind B., Brune K., Hinz B. Ceramide is involved in R(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 2003, 64:1189-1198.
28. Hinz B., Ramer R., Eichele K., Weinzierl U., Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 2004, 66:1643-1651.
29. Hinz B., Ramer R., Eichele K., Weinzierl U., Brune K. R(+)-Methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun 2004, 324:621-626.
30. Eichele K., Ramer R., Hinz B. R(+)-Methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway. Pharm Res 2009, 26:346-355.
31. Ramer R., Merkord J., Rohde H., Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 2010, 79:955-966.
32. Junglas B., Yu A.H., Welge-Lüssen U., Tamm E.R., Fuchshofer R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp Eye Res 2009, 88:1065-1075.
33. 2 synthase-1. Mol Cancer Ther 2009, 8:2348-2355.
34. Jacobsson S.O., Wallin T., Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 2001, 299:951-959.
35. 2 cannabinoid receptors. Eur J Pharmacol 2004, 505:1-9.
36. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000, 1483:285-293.
37. 2, and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000, 278:790-796.
38. Wall M.E., Sadler B.M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983, 34:352-363.
39. 3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J Biol Chem 1993, 268:9517-9521.
40. Coleman R.A., Grix S.P., Head S.A., Louttit J.B., Mallett A., Sheldrick L. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994, 47:151-168.
41. Sirianni R., Chimento A., De Luca A., Zolea F., Carpino A., Rago V., et al. Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. J Biol Chem 2009, 284:28905-28916.
42. Ramer R., Brune K., Pahl A., Hinz B. R(+)-Methanandamide induces cyclooxygenase-2 espression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 2001, 286:1144-1152.
43. 2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003, 278:37937-37947.
44. 2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress. Hypertension 2008, 52:952-959.
45. Black A.T., Gray J.P., Shakarjian M.P., Mishin V., Laskin D.L., Heck D.E., et al. UVB light upregulates prostaglandin synthases and prostaglandin receptors in mouse keratinocytes. Toxicol Appl Pharmacol 2008, 232:14-24.
46. Zhang Y., McCluskey K., Fujii K., Wahl L.M. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 1998, 161:3071-3076.
47. 2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol 2004, 173:5458-5466.
48. Ramer R., Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 2008, 100:59-69.
49. Fernandez H.A., Kallenbach K., Seghezzi G., Grossi E., Colvin S., Scheider R., et al. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 1999, 82:156-162.
50. Guedez L., McMarlin A.J., Kingma D.V.V., Bennett T.A., Stetler-Stevenson M., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001, 158:1207-1215.
51. Akahane T., Akahane M., Shah A., Connor C.M., Thorgeirsson U.P. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res 2004, 301:158-167.
52. Zacchigna S., Zentilin L., Morini M., Dell'Eva R., Noonan D.M., Albini A., et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 2004, 11:73-80.
53. Zeng H., Briske-Anderson M. Prolonged butyrate treatment inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr 2005, 135:291-295.
54. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997, 74:111-122.
55. Sancéau J., Truchet S., Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003, 278:36537-36546.
56. 2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006, 66:10902-10910.
57. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1:re6.
58. Maihöfner C., Schlötzer-Schrehardt U., Gühring H., Zeilhofer H.U., Naumann G.O.H., Pahl A., et al. Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. Invest Ophthalmol Vis Sci 2001, 42:2616-2624.
59. Hinz B., Rösch S., Ramer R., Tamm E.R., Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human non-pigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J 2005, 19:1929-1931.